Skip to main content

Advertisement

Table 4 Prognostic values of clinical variables for predicting progression-free survival in 184 patients with metastatic renal cell carcinoma (all categorical variables) analyzed by using univariate and multivariate Cox regression models

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Variable Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Sex (men vs. women) 1.204 (0.806–1.799) 0.363   
Age (<65 vs. ≥65 years) 0.999 (0.983–1.016) 0.934   
Pathologic type (ccRCC vs. nccRCC) 1.408 (0.896–2.221) 0.138   
History of nephrectomy (yes vs. no) 1.103 (0.691–1.760) 0.681   
History of cytokine treatment (yes vs. no) 0.963 (0.667–1.391) 0.842   
Fuhrman grade (1–2 vs. 3–4 and unknown) 1.620 (1.260–2.081) <0.001* 1.181 (1.147–1.937) 0.196
Number of metastatic sites (1 vs. ≥ 2) 2.010 (1.384-2.918) <0.001* 1.601 (1.110–2.311) 0.012
MSKCC risk category (favorable and intermediate vs. poor) 1.927 (1.548–2.399) <0.001* 2.000 (1.060–2.154) <0.001
NLR (<2.2 vs. ≥2.2) 1.679 (1.201–2.347) 0.002* 1.511 (1.060–2.154) 0.022
Drug category (sorafenib vs. sunitinib) 1.036 (0.725–1.480) 0.847   
Pre-treatment serum albumin level (≥40.7 g/L vs. <40.7 g/L) 1.432 (1.034–1.984) 0.031* 0.913 (0.631–1.319) 0.627
Post-treatment serum albumin level (≥36.4 g/L vs. <36.4 g/L) 2.392 (1.637–3.494) <0.001* 2.113 (1.390–3.212) <0.001
  1. ccRCC, clear cell renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; NLR, neutrophil-to-lymphocyte ratio; MSKCC, Memorial Sloan Kettering Cancer Center; HR, hazard ratio; CI, confidence interval
  2. * Variables with P values <0.05 in univariate analysis were considered for multivariate analysis